List view / Grid view


Advancing vaccines with extracellular vesicles

27 September 2022 | By

Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles. These nano-size vesicles represent a potentially safe and simple subunit vaccine delivery platform that…

Targeting tau – chasing a treatment for Alzheimer’s

22 September 2022 | By

Alzheimer’s disease remains one of the largest challenges for the global ageing population. In this article, Victoria Rees, Editor of Drug Target Review, reviews some of the latest research, highlighting how progress has been made in understanding tau as well as how to potentially target this protein as a therapeutic strategy against…